Surgical technology company, Vicarious Surgical, appoints Stephen From as its new Chief Executive Officer.
In a significant shift for Vicarious Surgical, Stephen From has been appointed as the company's new Chief Executive Officer, effective from August 7, 2025 [1][2][3][4][5].
Prior to his new role, From served as the CEO of Aruna Bio, a biotech firm specialising in the development of neural exosomes for neurodegenerative diseases [1]. He brings over 20 years of leadership experience in the healthcare and financial industries to his new position.
Before Aruna Bio, From held the position of executive chairman at Kiora Pharmaceuticals (formerly EyeGate Pharmaceuticals), where he oversaw an initial public offering and multiple acquisitions and licensing transactions [1]. He also served as the CFO of Centelion, a biotech subsidiary of Sanofi-Aventis, and has a background in investment banking focused on life sciences [1].
Randy Clark, who previously held the position of president at Vicarious Surgical, announced his resignation in April [4]. Clark joined the company's board in the same month, but his tenure was brief, spanning just over a year [4]. According to his LinkedIn account, Clark is now an executive with Thermo Fisher Scientific [2].
Adam Sachs, the outgoing CEO, stated that From's leadership and experience are exactly what Vicarious Surgical needs at this pivotal stage [5]. Sachs will step down as CEO but will remain on the leadership team as company president and a member of the board [6].
Vicarious Surgical is currently preparing for the first human cases with its robot, and is working closely with UMass Memorial Medical Center to promote the adoption of its robotic surgery system [7]. The company's pivotal trial is focused on ventral hernia repair [8].
[1] - [8] are references to the provided bullet points.
- Stephen From's appointment as the new CEO of Vicarious Surgical, effective from August 7, 2025, is a significant shift, given his background in the healthcare and financial industries.
- From's experience includes leading Aruna Bio, a biotech firm specializing in neural exosomes for neurodegenerative diseases, and overseeing an initial public offering and multiple acquisitions at Kiora Pharmaceuticals.
- Prior to his new role, From also served as the CFO of Centelion, a biotech subsidiary of Sanofi-Aventis, and has a background in investment banking focused on life sciences.
- Randy Clark, who was previously the president at Vicarious Surgical, announced his resignation in April and has moved on to an executive position at Thermo Fisher Scientific.
- Adam Sachs, the outgoing CEO, believes From's leadership is crucial for Vicarious Surgical during its pivotal stage, as it prepares for the first human cases with its robot.
- The company is working closely with UMass Memorial Medical Center to promote the adoption of its robotic surgery system, and its pivotal trial is focused on ventral hernia repair.
- This news of leadership changes and upcoming initiatives in healthcare technology and medtech sectors could potentially influence the earnings of other health-and-wellness, finance, technology, and business entities involved in AI, medical-conditions, and scientific advancements.
